微滴数字PCR检测慢性髓性白血病中第二代酪氨酸激酶抑制剂耐药的BCR::ABL1激酶域突变
本研究评估基于微滴数字PCR(ddPCR)的多重策略检测和定量携带第二代酪氨酸激酶抑制剂(2GTKI)耐药突变的转录本。在60份突变阴性样本中确定空白限,通过48份已用下一代测序(NGS)分析的样本验证准确性,突变可检出至0.5%且跨越3个对数级BCR::ABL1水平。回顾性分析513例对一线或二线TKI反应不佳的连续CML患者的NGS结果,提示靶向2GTKI耐药突变的ddPCR方法在伊马替尼警告反应患者中22%评为突变阴性,而在2GTKI警告反应患者中仅6%评为突变阴性。
要点
- ddPCR可检出BCR::ABL1突变低至0.5%,并跨越3个对数级BCR::ABL1水平。
- 在伊马替尼警告反应患者中,靶向2GTKI耐药突变的ddPCR将22%评为突变阴性;在2GTKI警告反应患者中仅6%评为突变阴性。
- ddPCR不能识别复合突变。
核心结论
- ddPCR是一种简便、准确、快速筛查2GTKI耐药突变的方法,可影响TKI选择,但ddPCR不能识别复合突变。
研究设计与样本
- 基于ddPCR的多重策略,用于检测和定量携带2GTKI耐药突变的转录本,并行定量e13a2、e14a2和e1a2 BCR::ABL1融合转录本以突变阳性占总BCR::ABL1转录本的百分比表示结果。
- 在60份突变阴性样本中确定空白限;通过进一步分析48份已用NGS研究的样本验证准确性。
- 回顾性审查513例对一线或二线TKI治疗反应不佳的连续CML患者的BCR::ABL1 NGS结果。
主要发现
- 突变可检出至0.5%,并跨越3个对数级BCR::ABL1水平。
- 回顾性审查513例连续CML患者提示,靶向2GTKI耐药突变的ddPCR方法在伊马替尼警告反应患者中22%评为突变阴性,而在2GTKI警告反应患者中仅6%评为突变阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- ddPCR不能识别复合突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
One of the indications for BCR::ABL1 mutation testing in chronic myeloid leukemia (CML) is when tyrosine kinase inhibitor therapy (TKI) needs to be changed for unsatisfactory response. In this study, we evaluated a droplet digital PCR (ddPCR)-based multiplex strategy for the detection and quantitation of transcripts harbouring mutations conferring resistance to second-generation TKIs (2GTKIs). Parallel quantitation of e13a2, e14a2 and e1a2 BCR::ABL1 fusion transcripts enables to express results as percentage of mutation positive- over total BCR::ABL1 transcripts. We determined the limit of blank in 60 mutation-negative samples. Accuracy was demonstrated by further analysis of 48 samples already studied by next generation sequencing (NGS). Mutations could be called down to 0.5% and across 3-logs of BCR::ABL1 levels. Retrospective review of BCR::ABL1 NGS results in 513 consecutive CML patients with non-optimal response to first- or second-line TKI therapy suggested that a ddPCR-based approach targeted against 2GTKI-resistant mutations would score samples as mutation-negative in 22% of patients with warning response to imatinib but only in 6% of patients with warning response to 2GTKIs. We conclude ddPCR represents an attractive method for easy, accurate and rapid screening for 2GTKI-resistant mutations impacting on TKI selection, although ddPCR cannot identify compound mutations.
引用
- Soverini S, De Santis S, Martelli M, et al. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022. PMID: 35908105. doi:10.1038/s41375-022-01660-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。